Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

KT-413

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Kymera Therap

Drug class:

IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader

Related drugs:

‹

›

CD79B mutation + TNFAIP3 mutation	Diffuse Large B Cell Lymphoma	CD79B mutation + TNFAIP3 mutation	Diffuse Large B Cell Lymphoma	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D
MYD88 L265P	Diffuse Large B Cell Lymphoma	MYD88 L265P	Diffuse Large B Cell Lymphoma	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	BTK inhibitor + KT-413 Sensitive: D – Preclinical BTK inhibitor + KT-413 Sensitive : D	BTK inhibitor + KT-413 Sensitive: D – Preclinical BTK inhibitor + KT-413 Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	rituximab + KT-413 Sensitive: D – Preclinical rituximab + KT-413 Sensitive : D	rituximab + KT-413 Sensitive: D – Preclinical rituximab + KT-413 Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D